NRSN

NeuroSense Therapeutics Ltd

1.69

Nov 13 • 3:59 PM ET -0.07 (-3.98%)

1.56

Aftermarket • 5:00 PM ET -0.13 (-7.69%)

Healthcare Biotechnology Israel Nano NASD

Peers: CLNN COYA MNOV ALZN ANVS PMN CRVO INMB AMLX CGTX

Scroll to Statements

Index	-
Market Cap	3.21M
Enterprise Value	-
Income	-
Sales	-
Book/sh	-
Cash/sh	-
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	16
IPO	Dec 09, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	-
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	-
Current Ratio	-
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-4.67
EPS next Q	-
EPS this Y	42.61%
EPS next Y	7.43%
EPS next 5Y	4.85%
EPS past 3/5Y	25.89% 21.42%
Sales past 3/5Y	- -
EPS Y/Y TTM	31.09%
Sales Y/Y TTM	-
EPS Q/Q	59.58%
Sales Q/Q	-
Earnings	Sep 02
EPS/Sales Surpr.	0.00% -

Insider Own	31.70%
Insider Trans	489.66%
Inst Own	0.17%
Inst Trans	-36.52%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-15.44%
SMA50	-59.16%
SMA200	-85.91%
Trades

Shs Outstand	1.90M
Shs Float	1.30M
Short Float	2.09%
Short Ratio	0.85
Short Interest	0.03M
52W High	25.40 -93.35%
52W Low	1.10 53.64%
Volatility	17.58% 19.67%
ATR (14)	0.41
RSI (14)	31.45
Beta	1.73
Rel Volume	0.57
Avg Volume	32.13K
Volume	18,305

Perf Week	0.60%
Perf Month	-46.69%
Perf Quarter	-80.44%
Perf Half Y	-89.78%
Perf YTD	-89.01%
Perf Year	-90.79%
Perf 3Y	-83.07%
Perf 5Y	-
Perf 10Y	-
Recom	2.33
Target Price	100.67
Prev Close	1.76
Price	1.69
Change %	-3.98%

Nov-02-26 09:00AM	NeuroSense to Strengthen PrimeC Canadian ALS Submission With New NfL Data (PR Newswire) -28.14%
Oct-29-26 11:30AM	NeuroSense to Present Integrated Clinical and Biomarker Evidence Shaping PrimeC's Phase 3 Development at NEALS 2026 (PR Newswire) -9.75%
Oct-19-26 08:25AM	NeuroSense Files U.S. Patent Application for Traumatic Brain Injury (PR Newswire) -13.19%
Oct-13-26 08:30AM	NeuroSense Secures Nasdaq Hearing Date as PrimeC Approaches Key Regulatory and Funding Milestones (PR Newswire)
Oct-02-26 04:15PM	NeuroSense Provides Update on Nasdaq Listing Compliance (PR Newswire)
12:43PM	Loading…
Sep-28-26 12:43PM	NeuroSense to Participate in the 5th Annual ROTH Healthcare Opportunities Conference (PR Newswire) -26.62%
Sep-25-26 04:30PM	NeuroSense Provides Business Update and Progress for the First Half of 2026 (PR Newswire) -6.08%
Sep-10-26 09:00AM	NeuroSense to Present at H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire) -17.21%
Aug-31-26 10:34AM	NeuroSense Rewrites the Standard ALS Playbook With a Faster, Leaner Path to Potential Approval (FinanceWire)
08:45AM	NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS (PR Newswire)
Aug-13-26 09:30AM	NeuroSense Issues CEO Letter to Shareholders (PR Newswire) -5.46%
Aug-06-26 11:29AM	NeuroSense Completes PrimeC Pre-NDS Process and Advances Toward December 2026 Filing with Health Canada (PR Newswire) -7.16%
Jul-22-26 08:30AM	NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS (PR Newswire) -7.14%
Jul-06-26 08:45AM	NeuroSense to Participate in Roth-Hosted KOL Webinar on the Future of ALS Treatment: "A Quest to Outrun ALS" (PR Newswire)
Jun-29-26 09:30AM	NeuroSense Achieves Primary Endpoint in Phase 2b ALS Study with Statistically Significant Reduction of TDP-43, the Defining Pathological Hallmark of ALS (PR Newswire) -6.27%
09:20AM	Loading…
Jun-25-26 09:20AM	NeuroSense Reports Positive Biomarker Findings from Phase 2 RoAD Proof-of-Concept Study of PrimeC in Alzheimer's Disease (PR Newswire)
Jun-22-26 09:00AM	EverythingALS to Host NeuroSense in a Community Event Named: PrimeC - Connecting the Dots (PR Newswire)
Jun-11-26 09:00AM	NeuroSense Granted South Korean Patent Covering PrimeC Composition for ALS (PR Newswire)
Jun-09-26 09:00AM	NeuroSense Therapeutics Receives Japanese Patent Grant for PrimeC Novel Composition (PR Newswire)
Apr-28-26 02:30PM	NeuroSense Announces Pricing of Insider-Led PIPE Financing (PR Newswire) +7.78%
Apr-06-26 09:20AM	NeuroSense Granted Brazilian Patent Covering PrimeC Composition (PR Newswire) -8.19%
Apr-03-26 10:02AM	NeuroSense Therapeutics Announces Receipt of Nasdaq Notifications Regarding Minimum Bid Price and Market Value Requirements (PR Newswire)
Mar-31-26 09:20AM	NeuroSense Therapeutics Reports Year End 2025 Financial Results and Provides Business Update (PR Newswire)
Mar-24-26 09:00AM	NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout (PR Newswire)
Mar-18-26 08:00AM	PrimeC New Data to Be Presented at AD/PD 2026 Conference (PR Newswire) -5.36%
Mar-16-26 11:33AM	JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity (PR Newswire) -5.61%
Mar-09-26 11:07AM	PrimeC Long-Term Survival Data to Be Presented at a Leading ALS Scientific Conference (PR Newswire)
Feb-18-26 09:05AM	NeuroSense Announces Statistically Significant 65% Reduction in Risk of Death and Greater than 14-Month Median Survival Benefit with PrimeC in ALS (PR Newswire) -14.69%
Feb-09-26 09:20AM	NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition (PR Newswire) +8.52%
Jan-21-26 08:30AM	NeuroSense Granted U.S. Patent for Treatment of Alzheimer's Disease (PR Newswire) -5.19%
08:45AM	Loading…
Jan-08-26 08:45AM	World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB (PR Newswire) +12.43%
Dec-22-25 09:17AM	NeuroSense Confirms Favorable Safety and Tolerability of PrimeC in an Alzheimer's Phase 2 Study (PR Newswire)
Dec-04-25 07:30AM	NeuroSense to Hold Pre-NDS Meeting with Health Canada in April 2026 (PR Newswire)
Nov-24-25 09:56AM	NeuroSense Receives FDA Clearance to Initiate Pivotal Phase 3 Trial for PrimeC in ALS (PR Newswire)
Nov-03-25 09:15AM	NeuroSense to Host Investor Webinar on December 8, 2025 (PR Newswire)
Oct-06-25 09:00AM	NeuroSense: PrimeC Produces Statistically Significant Reductions in Alzheimer's Disease Biomarkers (PR Newswire) -6.40%
Sep-10-25 02:30PM	NeuroSense's Drug Candidate Shows Early Signals of Benefit in Alzheimer's Patient-Derived Neurons (PR Newswire) +16.24%
Sep-04-25 08:49AM	NeuroSense Therapeutics Announces $500,000 Private Placement at Premium to Market Price (PR Newswire)
Aug-01-25 09:00AM	NeuroSense Provides Business Update and Progress for the First Half of 2025 (PR Newswire) -40.00%
Jul-22-25 08:42AM	Award-Winning Broadway, Television & Film Star Aaron Lazar Featuring NeuroSense CEO Alon Ben-Noon in a Special Live Podcast on ALS Science, PrimeC's Commercialization Strategies, and Community (PR Newswire)
May-07-25 08:45AM	NeuroSense Therapeutics Announces Successful Completion of Commercial Manufacturing Scale-Up for PrimeC in Preparation for Potential Canadian Market Launch (PR Newswire)
Apr-24-25 09:09AM	NeuroSense Therapeutics Releases Letter to Shareholders Outlining Clinical Progress, Regulatory Strategy, and Partnership Update (PR Newswire)
Apr-09-25 08:30AM	NeuroSense Therapeutics Announces Transformative Phase 2b MicroRNA Data, Highlighting PrimeC's Promise as a Disease-Modifying ALS Treatment (PR Newswire)
Apr-07-25 05:14PM	NeuroSense Therapeutics Reports Year End 2024 Financial Results and Provides Business Updates (PR Newswire)
Apr-04-25 09:10AM	NeuroSense Therapeutics to Present New Data from PrimeC's Phase 2b Trial in ALS at the Annual American Academy of Neurology Meeting (PR Newswire)
Mar-20-25 10:30AM	Market Alert: NeuroSense Therapeutics Advances Toward Early Canadian Commercialization of ALS Drug (Business Wire)
Mar-17-25 08:30AM	PESG Releases Report on NeuroSense Therapeutics: Groundbreaking ALS Therapy Signals Massive Potential Opportunity in Billion Dollar Treatment Landscape (Business Wire)
Jan-06-25 09:00AM	NeuroSense Regains Compliance with Nasdaq's Minimum Equity Requirement (PR Newswire)
Dec-23-24 09:00AM	NeuroSense Therapeutics Enters Binding Term Sheet to Advance PrimeC for ALS (PR Newswire) -8.09%
Dec-18-24 10:25AM	NeuroSense Provides Business Update and Third Quarter 2024 Financial Results (PR Newswire)
Dec-11-24 09:25AM	NeuroSense Receives Positive FDA Feedback on Phase 3 Study Design for PrimeC (PR Newswire) -10.76%
Dec-04-24 08:30AM	NeuroSense Announces Completion of PARADIGM Study Highlighting PrimeC's Significant Efficacy and Survival Benefits in ALS (PR Newswire) -5.31%
Dec-02-24 08:30AM	NeuroSense Therapeutics Announces $5 Million Private Placement at Premium to Market Price (PR Newswire) +14.27%
Nov-21-24 09:20AM	NeuroSense Therapeutics to Participate in the 2024 International Symposium on ALS/MND (PR Newswire) -7.08%
Oct-28-24 08:30AM	NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission (PR Newswire) +6.30%
Oct-24-24 08:30AM	New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients (PR Newswire) +5.22%
Oct-15-24 09:15AM	NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates (PR Newswire) -12.20%
Oct-09-24 09:00AM	NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada (PR Newswire)
Oct-07-24 09:00AM	NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting (PR Newswire)
Sep-24-24 09:05AM	NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's (PR Newswire)
09:00AM	NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule (PR Newswire)
Aug-30-24 04:30PM	NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire) +17.11% +10.09%
Aug-07-24 02:00PM	NeuroSense Therapeutics Announces Private Placement with Senior Management Participation at Premium to Market Price (PR Newswire)
Aug-01-24 09:15AM	NeuroSense Therapeutics Announces Positive Biomarker Data from ALS Phase 2b Clinical Trial (PR Newswire) -10.50%
Jul-09-24 09:27AM	NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression (PR Newswire) -19.11%
Jul-01-24 08:00AM	NeuroSense Demonstrates Statistically Significant Efficacy and Survival Benefits in People Living with ALS: The Promising Results from the 12-Month PARADIGM Study Highlight PrimeC's Potential as a Disease Modifying Drug (PR Newswire)
Jun-24-24 02:52PM	NRSN Stock Earnings: NeuroSense Therapeutics Misses EPS for Q1 2024 (InvestorPlace) -5.87%
09:00AM	NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results (PR Newswire)
Jun-21-24 04:30PM	NeuroSense Receives Delisting Notice from Nasdaq and Intends to Appeal (PR Newswire)
May-20-24 09:00AM	NeuroSense Vice President of R&D Shiran Zimri, Ph.D. to Participate in the 3rd Annual ALS Drug Development Summit (PR Newswire)
May-14-24 09:05AM	NeuroSense Partners with PhaseV to Optimize Upcoming ALS Phase 3 Trial Using Advanced Causal Machine Learning (PR Newswire)
May-07-24 08:45AM	NeuroSense Announces New Positive Data Analysis from PARADIGM Clinical Trial Demonstrating Statistically Significant Slowing of Disease Progression in High-Risk ALS Patients (PR Newswire)
May-02-24 09:19AM	NeuroSense Announces First Quarter 2024 Business Update (PR Newswire)
Apr-22-24 08:30AM	NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease (PR Newswire)
Apr-18-24 08:30AM	NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting (PR Newswire) -5.00%
Apr-12-24 08:30AM	NeuroSense to Present PARADIGM Data at the American Academy of Neurology Annual Meeting April 16, 2024 (PR Newswire)
Apr-10-24 07:16PM	NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurrent Private Placement (PR Newswire)
Apr-09-24 08:30AM	NeuroSense Collaborates with Lonza to Identify Exosome-based Biomarkers, in order to Advance Neurodegenerative Disease Treatments and Diagnostics (PR Newswire)
Apr-05-24 08:52PM	NRSN Stock Earnings: NeuroSense Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -17.48%
09:29AM	NeuroSense Announces Year End 2023 Financial Results and Provides Business Update (PR Newswire)
Feb-21-24 08:30AM	NeuroSense Reports Additional Positive Results from its ALS Phase 2b PARADIGM Trial (PR Newswire) -8.76%
Feb-07-24 09:27AM	NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule (PR Newswire)
Jan-30-24 08:30AM	NeuroSense's (NASDAQ:NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024 (ACCESSWIRE)
Jan-09-24 08:45AM	NeuroSense Recaps Positive 2023 Achievements Including Statistically Significant Slowing of Disease Progression in Phase 2b ALS Trial of PrimeC and Highlights Anticipated 2024 Catalysts (PR Newswire)
Dec-27-23 05:00PM	NeuroSense Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement (PR Newswire)
Dec-14-23 09:24AM	NeuroSense Reports New Data: Statistically Significant Clinical Efficacy in Phase 2b ALS Trial (PR Newswire) +27.93%
Dec-05-23 08:00AM	NeuroSense's Phase 2b ALS Trial Achieves Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints (PR Newswire) -24.16%
Dec-04-23 04:01PM	NeuroSense to Report Phase 2b ALS Topline Primary Safety and Tolerability & Secondary Clinical Efficacy Endpoints on December 5, 2023 (PR Newswire) +15.50%
Nov-28-23 08:45AM	NeuroSense Announces Third Quarter 2023 Financial Results and Provides Business Update (PR Newswire) +5.83%
Nov-13-23 09:20AM	NeuroSense Receives U.S. FDA Confirmation of CMC Strategy for PrimeC in Preparation for Pivotal Phase 3 in ALS and Commercial Readiness (PR Newswire)
Nov-09-23 09:00AM	NeuroSense Therapeutics to Present at Upcoming U.S. and European ALS Conferences (PR Newswire)
Nov-06-23 08:30AM	NeuroSense Completes Dosing of Last Patient in the Double-Blind Segment of Phase 2b ALS Trial: Topline Clinical Efficacy Results Expected December 2023 (PR Newswire) +12.93%
Nov-01-23 09:00AM	NeuroSense Therapeutics to Participate in BIO-Europe Fall (PR Newswire)
Oct-19-23 10:30AM	Renowned ALS Researcher Confirms The Efficacy Of NeuroSense Therapeutics Lead Drug Candidate, PrimeC (ACCESSWIRE)
Oct-17-23 08:30AM	NeuroSense CEO Provides Q3 2023 Update (PR Newswire)
Oct-04-23 09:10AM	NeuroSense's PrimeC Demonstrates Outstanding Effect on ALS Survival in Innovative iPSC Model (PR Newswire) -7.91%
07:00AM	Presenting on the Emerging Growth Conference 63 Day 2 on October 5 Register Now (GlobeNewswire)
Oct-03-23 07:00AM	Presenting on the Emerging Growth Conference 63 Day 1 on October 4 Register Now (GlobeNewswire)
Oct-02-23 08:46AM	NeuroSense Ends its At-The-Market Equity Offering Program: Company is Fully Funded Beyond Clinical Phase 2b ALS Results (PR Newswire)
Sep-20-23 09:05AM	European Medicines Agency Grants NeuroSense SME Status (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Eisenberg Or	Chief Financial Officer	Jun 16 '26	Buy	0.80	250,000	200,000	1,504,050	Jun 17 04:30 PM
Ben-Noon Alon	Chief Executive Officer	Jun 16 '26	Buy	0.80	250,000	200,000	4,534,233	Jun 17 04:30 PM

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm offers PrimeC, a therapy for amyotrophic lateral sclerosis (ALS). It also conducts testing of product candidates for the treatment of Parkinson's and Alzheimer's diseases. The company was founded by Alon Ben-Noon on February 13, 2017 and is headquartered in Herzliya, Israel.

Co-FounderMr. Alon Ben-Noon

Chief Financial OfficerMr. Or Eisenberg

Chief Technology OfficerDr. Niva Russek-Blum Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

NRSN

NeuroSense Therapeutics Ltd

Upgrade your Finviz experience

All the Features.
Half the Price.